Synthesis and evaluation of new Hsp90 inhibitors based on a 1,4,5-trisubstituted 1,2,3-triazole scaffold

Journal of Medicinal Chemistry

Volumn 57, Issue 6, 2014, Pages 2258-2274

  Taddei, Maurizio ^a   Ferrini, Serena ^a   Giannotti, Luca ^a   Corsi, Massimo ^a   Manetti, Fabrizio ^a   Giannini, Giuseppe ^b   Vesci, Loredana ^b   Milazzo, Ferdinando M ^b   Alloatti, Domenico ^b   Guglielmi, Mario B ^b   Castorina, Massimo ^b   Cervoni, Maria L ^b   Barbarino, Marcella ^b   Foderà, Rosanna ^b   Carollo, Valeria ^b   Pisano, Claudio ^b   Armaroli, Silvia ^c   Cabri, Walter ^b  

^a UNIVERSITY OF SIENA   (Italy)

^b Sigma Tau SpA   (Italy)

^c Sigma Tau Research Switzerland   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,3 TRIAZOLE DERIVATIVE; ADENOSINE TRIPHOSPHATE; ALKYL GROUP; AMIDE; AZIDE; CARBOXYLIC ACID DERIVATIVE; CUMENE; HEAT SHOCK PROTEIN 70; HEAT SHOCK PROTEIN 90; HEAT SHOCK PROTEIN 90 INHIBITOR; LUMINESPIB; POLYCYCLIC AROMATIC HYDROCARBON DERIVATIVE; PROPIONIC ACID DERIVATIVE; RESORCINOL; RUTHENIUM; SST 0287CL 1; UNCLASSIFIED DRUG; [1 [2,4 DIHYDROXYCUMENYL] 5 [4 (4 MORPHOLIN 4 YLMETHYL)PHENYL] 1H 1,2,3 TRIAZOL 4 YL](ETHYLAMINO)FORMALDEHYDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; BINDING AFFINITY; CATALYSIS; CONTROLLED STUDY; CYCLOADDITION; DRUG BINDING SITE; DRUG CYTOTOXICITY; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG SCREENING; DRUG SYNTHESIS; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOLECULAR DOCKING; MOUSE; NONHUMAN; PROTEIN EXPRESSION; SIMULATION; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; CATALYSIS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; COMPUTATIONAL BIOLOGY; FLOW CYTOMETRY; HSP90 HEAT-SHOCK PROTEINS; HUMANS; INDICATORS AND REAGENTS; ISOXAZOLES; MICE; MODELS, MOLECULAR; PROTEIN BINDING; RESORCINOLS; RUTHENIUM; SPECTROMETRY, FLUORESCENCE; STRUCTURE-ACTIVITY RELATIONSHIP; TRIAZOLES; X-RAY DIFFRACTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84897427667     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm401536b     Document Type: Article

References (34)

1. Sreedhar, A. S.; Csermely, P. Heat shock proteins in the regulation of apoptosis: new strategies in tumor therapy: a comprehensive review Pharmacol. Ther. 2004, 101, 227-257
2. Stravopodis, D. J.; Margaritis, L. H.; Voutsinas, G. E. Drug-mediated targeted disruption of multiple protein activities through functional inhibition of the Hsp90 chaperone complex Curr. Med. Chem. 2007, 14, 3122-3138
3. Banerji, U. Heat shock protein 90 as a drug target: some like it hot Clin. Cancer Res. 2009, 1, 9-14
4. Neckers, L. Heat shock protein 90: the cancer chaperone J Biosci. 2007, 32, 517-530
5. Ho, N.; Li, A.; Li, S.; Zhang, H. Heat shock protein 90 and role of its chemical inhibitors in treatment of hematologic malignancies Pharmaceuticals 2012, 5, 779-801
6. Taldone, T.; Zatorska, D.; Patel, P. D.; Zong, H.; Rodina, A.; Ahn, J. H.; Moulick, K.; Guzman, M. L.; Chiosis, G. Design, synthesis, and evaluation of small molecule Hsp90 probes Bioorg. Med. Chem. 2011, 19, 2603-2614
7. Chen, G.; Bradford, W. D.; Seidel, C. W.; Li, R. Hsp90 stress potentiates rapid cellular adaptation through induction of aneuploidy Nature 2012, 482, 246-250
8. Lu, X.; Wang, L.; Ruden, M. D. Hsp90 Inhibitors and the reduction of anti-cancer drug resistance by non-genetic and genetic mechanisms Pharmaceuticals 2012, 5, 890-898
9. Turbyville, T. J.; Kithsiri Wijeratne, E. M.; Liu, M. X.; Burns, A. M.; Seliga, C. J.; Luevano, L. A.; David, C. L.; Faeth, S. H.; Whitesell, L.; Gunatilaka, A. A. L. Search for Hsp90 inhibitors with potential anticancer activity: isolation and SAR studies of radicicol and monocillin I from two plant-associated fungi of the Sonoran desert J. Nat. Prod. 2006, 69, 178-184
10. Neckers, L.; Workman, P. Hsp90 molecular chaperone inhibitors: Are we there yet? Clin. Cancer Res. 2012, 18, 64-76
11. Patki, J. M.; Pawar, S. S. Hsp90: chaperone-me-not Pathol. Oncol. Res. 2013, 19, 631-640
12. Chang, D.-J.; An, H.; Kim, K-s.; Kim, H. H.; Jung, J.; Lee, M. L.; Kim, N.-J.; Han, Y. T.; Yun, H.; Lee, S.; Lee, G.; Lee, S.; Lee, J. S.; Cha, J.-H.; Park, J.-H.; Park, J. W.; Lee, S.-C.; Kim, S. G.; Kim, J. H.; Lee, H. Y.; Kim, K.-W.; Suh, W.-G. Design, synthesis, and biological evaluation of novel deguelin-based heat shock protein 90 (Hsp90) inhibitors targeting proliferation and angiogenesis J. Med. Chem. 2012, 55, 10863-10884
13. Soga, S.; Akinaga, S.; Shiotsu, Y. Hsp90 inhibitors as anti-cancer agents, from basic discoveries to clinical development Curr. Pharm. Des. 2013, 19, 366-376
14. Biamonte, M. A.; Van de Water, R.; Arndt, J. W.; Scannevin, R. H.; Perret, D.; Lee, W.-C. Heat shock protein 90: inhibitors in clinical trials J. Med. Chem. 2010, 53, 3-17
15. Richter, K.; Soroka, J.; Skalniak, L.; Leskovar, A.; Hessling, M.; Reinstein, J.; Buchner, J. Conserved conformational changes in the ATPase cycle of human Hsp90 J. Biol. Chem. 2008, 283, 17757-17765
16. Hanessian, S.; Auzzas, L.; Larsson, A.; Zhang, J.; Giannini, G.; Gallo, G.; Ciacci, A.; Cabri, W. Vorinostat-like molecules as structural, stereochemical, and pharmacological tools ACS Med. Chem. Lett. 2010, 1, 70-74
17. Botta, C. B.; Cabri, W.; Cini, E.; De Cesare, L.; Fattorusso, C.; Giannini, G.; Persico, M.; Petrella, A.; Rondinelli, F.; Rodriquez, M.; Russo, A.; Taddei, M. Oxime amides as a novel zinc binding group in histone deacetylase inhibitors: synthesis, biological activity, and computational evaluation J. Med. Chem. 2011, 54, 2165-2182
18. Baruchello, R.; Simoni, D.; Grisolia, G.; Barbato, G.; Marchetti, P.; Rondanin, R.; Mangiola, S.; Giannini, G.; Brunetti, T.; Alloatti, D.; Gallo, G.; Ciacci, A.; Vesci, L.; Castorina, M.; Milazzo, F. M.; Cervoni, M. L.; Guglielmi, M. B.; Barbarino, M.; Foderà, R.; Pisano, C.; Cabri, W. Novel 3,4-isoxazolediamides as potent inhibitors of chaperone heat shock protein 90 J. Med. Chem. 2011, 54, 8592-8604
19. Brough, P. A.; Aherne, W.; Barril, X.; Borgognoni, J.; Boxall, K.; Cansfield, J. E.; Cheung, K.-M. J.; Collins, I.; Davies, N. G. M.; Drysdale, M. J.; Dymock, B.; Eccles, S. E.; Finch, H.; Fink, A.; Hayes, A.; Howes, R.; Hubbard, R. E.; James, K.; Jordan, A. M.; Lockie, A.; Martins, V.; Massey, A.; Matthews, T. P.; McDonald, E.; Northfield, C. J.; Pearl, L. H.; Prodromou, C.; Ray, S.; Raynaud, F. I.; Roughley, S. D.; Sharp, S. Y.; Surgenor, A.; Walmsley, D. L.; Webb, P.; Wood, M.; Workman, P.; Wright, L. 4,5-Diarylisoxazole Hsp90 chaperone inhibitors: potential therapeutic agents for the treatment of cancer J. Med. Chem. 2008, 51, 196-218
20. Cikotiene, I.; Kazlauskas, E.; Matuliene, J.; Michailoviene, V.; Torresan, J.; Jachno, J.; Matulis, D. 5-Aryl-4-(5-substituted-2,4- dihydroxyphenyl)-1,2,3-thiadiazoles as inhibitors of Hsp90 chaperone Bioorg. Med. Chem. Lett. 2009, 19, 1089-1092
21. Hong, T.-J.; Park, H.; Kim, Y.-J.; Jeong, J.-H.; Hahn, J.-S. Identification of new Hsp90 inhibitors by structure-based virtual screening Bioorg. Med. Chem. Lett. 2009, 19, 4839-4842
22. McCleese, J. K.; Bear, M. D.; Fossey, S. L.; Mihalek, R. M.; Foley, K. P.; Ying, W.; Barsoum, J.; London, C. A. The novel Hsp90 inhibitor STA-1474 exhibits biologic activity against osteosarcoma cell lines Int. J. Cancer. 2009, 125, 2792-2801
23. Chimmanamada, D.; Burlinson, J. A.; Ying, W.; Sun, L.; Schweizer, S. M.; Zhang, S.; Demko, Z.; James, D.; Prezwloka, T. Triazole compounds that modulate Hsp90 activity. US2011105483 (A1), 2011.
24. Majireck, M. M.; Weinreb, S. M. A Study of the scope and regioselectivity of the ruthenium-catalyzed [3 + 2]-cycloaddition of azides with internal alkynes J. Org. Chem. 2006, 71, 8680-8683
25. Spiteri, C.; Moses, J. E. Copper-catalyzed azide-alkyne cycloaddition: regioselective synthesis of 1,4,5-trisubstituted 1,2,3-triazoles Angew. Chem., Int. Ed. 2010, 49, 31-33
26. 50 = 1 nM). For the limits of the assay see the following: Kim, J.; Felts, S.; Llauger, L.; He, H.; Huezo, H.; Rosen, N.; Chiosis, G. Development of a fluorescence polarization assay for the molecular chaperone Hsp90 J. Biomol. Screening 2004, 9, 375-381
27. LC/MS analysis showed that compound 44 is stable under conditions employed in the FP assay. For resorcinol esterification in order to get an effective pro-drug see the following: London, C. A.; Bear, M. D.; McCleese, J.; Foley, K. P.; Paalangara, R.; Inoue, T.; Ying, W.; Barsoum, J. Phase I evaluation of STA-1474, a prodrug of the novel Hsp90 inhibitor ganetespib, in dogs with spontaneous cancer PLoS One 2011, 6, e2701
28. Compound 18 and NVP-AUY922 bind Hsp90 comparably with the diverse STA-9090 (ganatesib): Shimamura, T.; Perera, S. A.; Foley, K. P.; Sang, J.; Rodig, S. J.; Inoue, T.; Chen, L.; Li, D.; Carretero, J.; Li, Y.-C.; Sinha, P.; Carey, C. D.; Borgman, C. L.; Jimenez, J.-P.; Meyerson, M.; Ying, W.; Barsoum, J.; Wong, K.-K.; Shapiro, G. I. Ganetespib (STA-9090), a nongeldanamycin Hsp90 inhibitor, has potent antitumor activity in vitro and in vivo models of non-small cell lung cancer Clin. Cancer Res. 2012, 18, 4973-4982
29. Koga, F.; Tsutsumi, S.; Neckers, L. M. Low dose geldanamycin inhibits hepatocyte growth factor and hypoxia-stimulated invasion of cancer cells Cell Cycle 2007, 6, 1393-402
30. Maulik, G.; Kijima, T.; Ma, P. C.; Ghosh, S. K.; Lin, J.; Shapiro, G. I.; Schaefer, E.; Tibaldi, E.; Johnson, B. E.; Salgia, R. Modulation of the c-Met/hepatocyte growth factor pathway in small cell lung cancer Clin. Cancer Res. 2002, 8, 620-7
31. Screening was performed by Reaction Biology Corp., Malvern, PA. See the following: Auzzas, L.; Larsson, A.; Matera, R.; Baraldi, A.; Deschênes-Simard, B.; Giannini, G.; Cabri, W.; Battistuzzi, G.; Gallo, G.; Ciacci, A.; Vesci, L.; Pisano, C.; Hanessian, S. Non-natural macrocyclic inhibitors of histone deacetylases: design, synthesis, and activity J. Med. Chem. 2010, 53, 8387-8399
32. Kekatpure, V. D.; Dannenberg, A. J.; Subbaramaiah, K. HDAC6 modulates Hsp90 chaperone activity and regulates activation of aryl hydrocarbon receptor signaling J. Biol. Chem. 2009, 284, 7436-7445
33. Bali, P.; Pranpar, M.; Bradner, J.; Balasis, M.; Fiskus, W.; Guo, F.; Rocha, K.; Kumaraswamy, S.; Boyapalle, S.; Atadja, P.; Seto, E.; Bhalla, K. Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90 J. Biol. Chem. 2005, 280, 26729-26734
34. Rao, R.; Fiskus, W.; Yang, Y.; Lee, P.; Joshi, R.; Fernandez, P.; Mandawat, A.; Atadja, P.; Bradner, J. E.; Bhalla, K. HDAC6 inhibition enhances 17-AAG mediated abrogation of Hsp90 chaperone function in human leukemia cells Blood 2008, 112, 1886-1893